TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25885011
Drug: basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: basic treatment (stimulant + parent training + placebo)
Study: 25885011
Drug: augmented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: augmented treatment
Study: 9374341
Drug: Nalmefene (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene (1 mg or 1 microg/kg)
Study: 20507387
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (HD-IVIG) at a dosage of 400 mg/kg per day for 5 days as an adjuvant therapy with systemic steroid therapy and/or immunosuppressive agents.
Study: 3440636
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg
Study: 8426316
Drug: Monofocal implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monofocal implant (Group 1)
Study: 8426316
Drug: Multifocal implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifocal implant (Group 2)
Study: 3501902
Drug: Dipyridamole (DP)
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole (DP) 75 mg and Acetylsalicylic acid (ASA) 325 mg thrice daily for 3 months
Study: 29055624
Drug: Cumulative illness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative illness rating scale‐geriatrics (CIRS‐G)
Study: 29055624
Drug: Instrumental activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrumental activities of daily living (IADL) from GA
Study: 27865535
Drug: Intratympanic methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic methylprednisolone (62.5 mg/mL)
Study: 27865535
Drug: Intratympanic gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic gentamicin (40 mg/mL)
Study: 22902096
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg daily)
Study: 20863398
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement (IS) - 20 mg iron
Study: 20863398
Drug: Iron +
Normalized name: Celebrate Iron + C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron + folic acid supplement (IFS) - 12.5 mg iron
Study: 20863398
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplement (MMS) - 10 mg iron
Study: 20863398
Drug: Micronutrient-fortified complementary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient-fortified complementary food (FCF) - 10 mg iron
Study: 20863398
Drug: Zinc +
Normalized name: GNP Cal Mag Zinc + D Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc + iron + ascorbic acid fortified water (FW) - 6.7 mg iron
Study: 12916465
Drug: Multimodality treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality treatment
Study: 8979323
Drug: Specific, localized,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific, localized, exercise therapy
Study: 1490530
Drug: Continuous bronchodilator
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous bronchodilator treatment
Study: 1490530
Drug: Symptomatic bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic bronchodilator treatment
Study: 3874038
Drug: Sulindac sulfoxide
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac sulfoxide (200 mg b.i.d.)
Study: 3874038
Drug: Sulindac sulfide
Normalized name: Sulindac sulfide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac sulfide (100 mg b.i.d.)
Study: 3874038
Drug: Aspirin (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (650 mg q.i.d.)
Study: 27375126
Drug: Universal door-to-door
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal door-to-door delivery of HIV testing and referral to prevention and treatment services with immediate offer of anti-retroviral treatment regardless of clinical status
Study: 27375126
Drug: Universal door-to-door
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal door-to-door delivery of HIV testing and referral to prevention and treatment services with offer of treatment in-line with national guidelines
Study: 24807330
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Indomethacin and antibiotics vs Control)
Study: 15860753
Drug: Salmeterol in
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol in combination with FP
Study: 12190841
Drug: E2 1
Normalized name: PGE2 10 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 1 mg daily plus intermittent NGM 90 micro g (3 days off, 3 days on)
Study: 12190841
Drug: E2 2
Normalized name: PGE2 20 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 2 mg plus constant NETA 1 mg daily
Study: 10530636
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride (50 to 150 mg/d)
Study: 6988942
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg 3 times a day and 400 mg nocte (standard dose)
Study: 28118062
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (500 mg three times per day for two weeks)
Study: 19233765
Drug: Intermittent antegrade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent antegrade blood cardioplegia with 300 mg of NAC
Study: 17578983
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection group (droperidol 2.5 mg)
Study: 17578983
Drug: Continuous group
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous group (droperidol 1.25 mg/day)
Study: 30747707
Drug: On-demand treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand treatment (ODT) with vWF/FVIII concentrates
Study: 29437056
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g intra-articularly after closure of the wound
Study: 29437056
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 10 mg/kg IV
Study: 20124114
Drug: 1.2-g/d omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2-g/d omega-3 PUFA
Study: 11920412
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg, intravenous loading dose at weeks 0, 2, and 6)
Study: 15374786
Drug: Tirofiban plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban plus heparin
Study: 31037994
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg daily
Study: 21499703
Drug: Gefarnate 50
Normalized name: gefarnate
DrugBank: Gefarnate (DB12079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefarnate 50 mg twice daily
Study: 31613432
Drug: Conservative oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative oxygen therapy
Study: 24480677
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg tofacitinib
Study: 24480677
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tofacitinib
Study: 24480677
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg tofacitinib
Study: 21761705
Drug: Oral antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antihistamine 10 mg everyday for one week (group CA)
Study: 21761705
Drug: No loratadine
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No loratadine tablets 10 mg everyday for one week (group CB)
Study: 16151422
Drug: Busulfan 16
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan 16 mg/kg + cyclophosphamide 200 mg/kg + antilymphocyte globulin
Study: 12875349
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (generic gliclazide)
Study: 12875349
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Diamicron)
Study: 10647194
Drug: Melatonin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (6 mg at 22.00)
Study: 8690104
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (50 mg daily on days 1 to 10 of the menstrual cycle) and estrogen (35 microg ethinyl E2 daily on days 1 to 21)
Study: 6147051
Drug: Oxmetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxmetidine 200 mg
Study: 31950597
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) with a dose of 66 Gy in 33 fractions from parallel opposed lateral beams.
Study: 28435464
Drug: Omalizumab 300
Normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab 300 mg subcutaneously every 4 weeks for 12 weeks
Study: 25801872
Drug: Guideline-recommended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended treatment (SBP <180 mm Hg)
Study: 27550722
Drug: Combined preoperative
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preoperative oral antibiotics (metronidazole and kanamycin) and perioperative intravenous antibiotics (cefmetazole) (oral/IV group)
Study: 27550722
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (cefmetazole) alone (IV-only group)
Study: 23665990
Drug: Concomitant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant treatment (omeprazole 20 mg/12 h, amoxicillin 1 g/12 h, clarithromycin 500 mg/12 h, metronidazole 500 mg/12 h for 10 days)
Study: 23665990
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (omeprazole 20 mg/12 h and amoxicillin 1 g/12 h for 5 days, followed by omeprazole 20 mg/12 h, clarithromycin 500 mg/12 h, and metronidazole 500 mg/12 h for 5 days)
Study: 16868694
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg b.i.d starting the day of surgery, discontinued 15 days after catheter removal.
Study: 3728926
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 4 mg + intravenous naloxone 2 mg for 12 hours
Study: 3511767
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 4 mg
Study: 8034388
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone
Study: 3728926
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 mg morphine intramuscularly + 20 ml epidural saline)
Study: 29512481
Drug: DPIV 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPIV 4 μg with alum
Study: 29512481
Drug: DPIV 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPIV 1 μg + AS03B
Study: 15361722
Drug: Amoxicillin/clavulanate (45/6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (45/6.4 mg/kg divided twice daily)
Study: 7518981
Drug: Terazosin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (10 mg once daily)
Study: 23121256
Drug: Jessner's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jessner's solution peels
Study: 2211568
Drug: Buspirone 5
Normalized name: busPIRone 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 5 mg t.i.d.
Study: 24315572
Drug: Polysomnographic sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysomnographic sleep during inpatient treatment
Study: 18506008
Drug: Ambrisentan monotherapy
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ambrisentan monotherapy
Study: 18388356
Drug: Acetazolamide (Acz)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (Acz) 250 mg/d for 12 weeks
Study: 15807672
Drug: Doxycycline twice
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline twice a day for the first month, once a day for the second and third months.
Study: 12038039
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei and L. acidophilus strains CERELA (1.5 g each)
Study: 10217552
Drug: Contingent voucher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingent voucher incentives (n = 19) for each consecutive naltrexone dose ingested
Study: 10158377
Drug: Atherectomy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atherectomy treatment of bifurcation lesions
Study: 10158377
Drug: Angioplasty treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angioplasty treatment of bifurcation lesions
Study: 2526999
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (220 mg Zn sulfate orally)
Study: 106965
Drug: standard prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard prophylaxis administered to 9 patients
Study: 21855592
Drug: 9 μg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 μg ID-TIV
Study: 21855592
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg ID-TIV
Study: 21855592
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg IM VA-TIV
Study: 9209168
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g soy protein
Study: 9209168
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g soy protein
Study: 9209168
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g soy protein
Study: 16353603
Drug: Etiocholanedione (ED),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etiocholanedione (ED), 4 gm daily
Study: 24942380
Drug: Phototherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phototherapy with 30 J dose
Study: 16396746
Drug: Reference treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference treatment modalities
Study: 1486224
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (MCF: mitoxantrone, cyclophosphamide, 5‐fluorouracil)
Study: 9462526
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) at therapeutic concentrations
Study: 9462526
Drug: Enoxaparin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.25 U/mL)
Study: 9462526
Drug: Argatroban (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (1 ng/mL)
Study: 7622771
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg b.i.d.) + Coamoxiclav (1 g b.i.d.) for 3 weeks
Study: 7622771
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg b.i.d.) + Coamoxiclav (1 g b.i.d.) for 6 weeks
Study: 22374183
Drug: Troponin I
Normalized name: Troponin I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin I ≥0.040 μg/L (n=497)
Study: 22374183
Drug: NT‐proBNP <387
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT‐proBNP <387 ng/L
Study: 22374183
Drug: NT‐proBNP >1402
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT‐proBNP >1402 ng/L
Study: 10485531
Drug: Irrigating balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigating balanced salt solution supplemented with vancomycin (10 microg/ml)
Study: 1657505
Drug: L‐[1‐13C]leucine continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐[1‐13C]leucine continuous infusion
Study: 1657505
Drug: Flooding amount
Normalized name: Adenosine 0.0006 g in 1.5 mL TOPICAL CREAM [CAVIALL Aqua Flood Water]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flooding amount of L‐[1‐13C]leucine
Study: 1446756
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol
Study: 12519036
Drug: Ibuprofen isobutanolammonium
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen isobutanolammonium
Study: 1819034
Drug: EAA in
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EAA in a routine dose
Study: 1819034
Drug: EAA in
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EAA in a much smaller dosage
Study: 25994567
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA therapy
Study: 15808754
Drug: Hyperglycemia (defined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (defined as glucose > or =7.8 mmol/l or 140 mg/dl)
Study: 15808754
Drug: Non-hyperglycemic patients
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-hyperglycemic patients (glucose < 7.8 mmol/l)
Study: 20125070
Drug: Hyperbaric levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric levobupivacaine (13.5 mg, intrathecally in 3 mL)
Study: 20125070
Drug: Isobaric levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric levobupivacaine (13.5 mg, intrathecally in 3 mL)
Study: 8673823
Drug: Ivermectin treatment
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin treatment (at least three doses)
Study: 8673823
Drug: Ivermectin treatment
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin treatment (annual treatment interval)
Study: 6416853
Drug: Oral 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 25-hydroxyvitamin D3 treatment
Study: 6416853
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in absorption on treatment
Study: 30808623
Drug: COBRA (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA (combination of sulfasalazine, low-dose methotrexate, and initially high, step-down prednisolone)
Study: 27731538
Drug: Methotrexate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (50 mg/m2)
Study: 15346750
Drug: Immediate provisional
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate provisional restoration of Osseotite implants
Study: 11334210
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (CT)
Study: 373088
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg levamisole tablets
Study: 21618678
Drug: Anticoagulants (enoxaparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (enoxaparin, unfractionated heparin, fondaparinux, bivalirudin)
Study: 11443205
Drug: Pegvisomant (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant (1 mg/kg)
Study: 9522024
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (CH) 500 mg as drinking solution
Study: 9522024
Drug: Chloraldurat rot
Normalized name: Sheep-rot Whole
DrugBank: Centella asiatica (DB14256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloraldurat rot (CR) one capsule
Study: 30877049
Drug: Attention Bias
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention Bias Modification Treatment (ABMT)
Study: 22018679
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 μg BID)
Study: 23850610
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) administration of LIPO-4 vaccine
Study: 19884541
Drug: Triple intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple intrathecal therapy (methotrexate with cytarabine and hydrocortisone)
Study: 11381675
Drug: E5880 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5880 (300 micrograms or 1200 micrograms twice daily) administered intravenously for 14 days
Study: 8094828
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (IVMP) 500 mg daily for 5 days
Study: 3531936
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg pure porcine relaxin
Study: 27793204
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenously administered ferric carboxymaltose
Study: 24142084
Drug: Conventional cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cognitive therapy (CCT)
Study: 15766302
Drug: Once-weekly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly oral morphine
Study: 19926048
Drug: 0.50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg/kg enoxaparin
Study: 19926048
Drug: 0.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/kg enoxaparin
Study: 19926048
Drug: UFH (unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH (unfractionated heparin)
Study: 14657039
Drug: Protein supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplement (8 g carbohydrate, 10 g protein, 3 g fat)
Study: 14657039
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 g carbohydrate, 0 g protein, 0 g fat)
Study: 3671250
Drug: nifedipine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (up to 60 mg/day)
Study: 3671250
Drug: prazosin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: prazosin (up to 20 mg/day)
Study: 3671250
Drug: hydralazine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydralazine (up to 200 mg/day)
Study: 20118387
Drug: Prescription omega-3-acid
Normalized name: OMEGA-3 ACID
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription omega-3-acid ethyl esters plus atorvastatin (20 mg/d)